A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
BERENSON, J. R, YELLIN, O, VESCIO, R, SWIFT, R. A, KAZAMEL, T, HILGER, J. D, CHEN, C.-S, CARTMELL, A, WOLIVER, T, FLAM, M, BRAVIN, E, NASSIR, Y
Published in Leukemia (01.07.2012)
Published in Leukemia (01.07.2012)
Get full text
Journal Article
Medical and socioeconomic impact of uterine fibroids
Greenberg, M D, Kazamel, T I
Published in Obstetrics and gynecology clinics of North America (01.12.1995)
Published in Obstetrics and gynecology clinics of North America (01.12.1995)
Get more information
Journal Article
A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)
Kazamel, T., Berenson, J. R., Yellin, O., Boccia, R. V., Matous, J., Dressler, K. A., Nassir, Y., Rothstein, S., Swift, R.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM)
Yellin, O., Berenson, J. R., Kazamel, T., Chen, C., Cartmel, A., Woliver, T. B. S., Flam, M. S., Bravin, E. N., Nassir, Y., Vescio, R. A., Swift, R.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article